2nd Joint DIA/European Medicines Agency Innovation Forum: Is the EU Regulatory Framework Ready?

29-30 November 2010
Hotel London Marriott West India Quay, London, UK

Programme Co-Chairs

Iman Barilero
Divisional Director, Regulatory Development Strategy and Policy, H. Lundbeck A/S, Denmark

Marisa Papaluca Amati
Head of Scientific Support and Projects, European Medicines Agency, EU

The 2nd Joint DIA/European Medicines Agency Innovation Forum will provide an opportunity to address the progress of innovative medicines in legal, organisational and technical aspects of the pharmaceutical framework in Europe. It will address the implementation of the European Medicines Agency/CHMP think-tank report on innovative medicines and look at the direction of the Agency's road map to 2015. The Forum will involve, and enhance communication between stakeholders such as patient representatives, academia, regulators and industry scientists.

DIA®
www.diahome.org

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Programme Advisor

Patrick Le Courtois
Head of Human Medicines Development and Evaluation, European Medicines Agency, EU

Programme Committee

Eric Abadie
Chair, CHMP, Chair Pharmacogenomics Working Party, European Medicines Agency and General Directorate, Afssaps, France

Solange Corriol Rohou
Director, Regulatory Affairs, AstraZeneca, France representing EFPIA

Bruno Flamion
Professor, Clinical Pharmacology, University of Namur, Belgium and Chair, CHMP, Scientific Advice Working Party, European Medicines Agency

Detlef Niese
Head Development, External Affairs Novartis Pharma AG, Switzerland

Agnès Saint-Raymond
Head of Human Medicines Special Areas, European Medicines Agency, EU

Tomas Salmonson
Vice Chairman, CHMP, European Medicines Agency and MPA, Sweden

Christian Schneider
Chair CAT, European Medicines Agency, Acting Head, Division EU Cooperation/Microbiology, Paul-Ehrlich-Institute, Germany

Spiros Vamvakas
Head of Scientific Advice, European Medicines Agency, EU

Key Topics

- Current activities at EU level to ensure innovation in science translates into benefit for the patients and to public health. This includes the new pharmaceutical package, paediatric medicines, gene therapy and stem cells, information to patients and European Commission impact assessment of the clinical trial directive
- Impact of the implementation of the 2007 think-tank report on the European Medicines Agency activities and road map to 2015 to support enhanced regulatory decision-making and access to medicines
- Innovation in the pharmaceutical industry: Looking for examples of innovative approaches in portfolio selection for R&D strategy
- The availability of innovative medicines and unmet medical needs: Role of regulators and policy makers
- Progress with IMI

Who Will Attend

- Patient Groups
- Health Authorities
- Policy Makers
- Pharmaceutical Industry

FOR REGULAR PROGRAMME UPDATES, PLEASE VISIT WWW.DIAHOME.ORG

Contact: tamara.kohler@diaeurope.org
+41 61 225 51 57

REGISTER NOW!

www.diahome.org > "Conferences / Meetings" in the left hand navigation menu > "Find a Meeting" > "Keyword" 10105